The show that helps you maximize your wealth by turning complex financial situations into actionable advice. On Your Money. Your Mission., we answer the questions you’ve been asking about -- financial planning, investing, retirement and everything in between. Whether you’re navigating the complexities of the market or looking for the best ways to save or spend your money, tune in to hear from experienced financial advisors with JFG. Walk away from each episode with savvy tips and financial t ...
…
continue reading
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Recce Pharmaceuticals reaches midpoint in Phase II Trial for Topical Gel R327G
MP3•منزل الحلقة
Manage episode 444249215 series 2891889
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) CEO James Graham joins Proactive’s Tylah Tully to discuss progress in a Phase II clinical trial for the topical gel RECCE® 327 (R327G). Recce has formally reached the halfway point, with 15 patients successfully dosed. The trial is assessing the efficacy of R327G against Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including diabetic foot infections and other wound infections, which are areas of significant unmet medical need. Early data shows that R327G is well tolerated, with promising antibacterial effects observed across a range of infections. The trial aims to enrol 30 participants by the end of 2024. The clinical study locations have expanded, now including Barwon Health, Australian Clinical Research Network NSW and ACRN Melbourne, increasing access to this novel treatment. The global ABSSSI market was valued at US$1.34 billion in 2023 and is projected to grow to US$2.31 billion over the next decade. An interim clinical review is scheduled for mid-October 2024 with further results expected shortly thereafter. Graham expressed optimism about the trial’s progress and the potential impact of R327G on the growing global healthcare need for effective treatments against drug-resistant bacterial infections. #ProactiveInvestors #ReccePharmaceuticals #ASX #R327G #Phase2Trial #ABSSSI #WoundInfections #DiabeticFootInfections #ClinicalTrial #AntibacterialGel #BroadSpectrumAntimicrobial #SkinInfections #DrugResistantBacteria #HealthcareInnovation #BarwonHealth #ClinicalResearch #Australia #InfectiousDiseases #BacterialInfections #MedicalResearch #Biotechnology #TGA #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 حلقات
MP3•منزل الحلقة
Manage episode 444249215 series 2891889
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) CEO James Graham joins Proactive’s Tylah Tully to discuss progress in a Phase II clinical trial for the topical gel RECCE® 327 (R327G). Recce has formally reached the halfway point, with 15 patients successfully dosed. The trial is assessing the efficacy of R327G against Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including diabetic foot infections and other wound infections, which are areas of significant unmet medical need. Early data shows that R327G is well tolerated, with promising antibacterial effects observed across a range of infections. The trial aims to enrol 30 participants by the end of 2024. The clinical study locations have expanded, now including Barwon Health, Australian Clinical Research Network NSW and ACRN Melbourne, increasing access to this novel treatment. The global ABSSSI market was valued at US$1.34 billion in 2023 and is projected to grow to US$2.31 billion over the next decade. An interim clinical review is scheduled for mid-October 2024 with further results expected shortly thereafter. Graham expressed optimism about the trial’s progress and the potential impact of R327G on the growing global healthcare need for effective treatments against drug-resistant bacterial infections. #ProactiveInvestors #ReccePharmaceuticals #ASX #R327G #Phase2Trial #ABSSSI #WoundInfections #DiabeticFootInfections #ClinicalTrial #AntibacterialGel #BroadSpectrumAntimicrobial #SkinInfections #DrugResistantBacteria #HealthcareInnovation #BarwonHealth #ClinicalResearch #Australia #InfectiousDiseases #BacterialInfections #MedicalResearch #Biotechnology #TGA #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 حلقات
Semua episod
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.